The combine vaccine helps decrease the load on healthcare and reduce the number of injections administered to a child in the first years of life

Manufacturer and developer – NPO Microgen (Nacimbio holding)

Vaktrivir is the first domestically made combined live-culture measles, rubella, parotitis vaccine.

Combined vaccines are recommended for use by Russian and international experts in immunoprophylaxis of infectious diseases. Multiple components ensure protection of patients against a more viruses using just one injection and reduce the load on medical personnel.

The vaccine contains components produced by the full cycle process in Russia and well-proven during long-term application as measles, rubella and parotitis monovaccines and divaccines. Clinical studies of the preparation have shown its safety and ability to induce stable immunity to the three diseases. The vaccine is intended for immunization of children aged 12 months and 6 years.

Vaktrivir is produced on quail embryonic fibroblast (QEF) cell culture. The use of QEF cell culture for vaccine production eliminates the risk of type I hypersensitivity anaphylactic reactions provoked by chicken protein.

Features

• One injection protects against three diseases.

• The vaccinal process is asymptomatic in most of vaccinated patients.

• The vaccine has been available for mass vaccination under the National Immunization Schedule since 2021.

• It is approved for use in children from 12 months.

• To reduce sensitization, Japanese quail embryonic fibroblast cell cultures are used in the vaccine formulation.